Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: A prospective randomized study

Endocrine Journal

Volumn 57, Issue 12, 2010, Pages 1035-1044

  Shen, Ming ^a   Shou, Xuefei ^a   Wang, Yongfei ^a   Zhang, Zhaoyun ^a   Wu, Jinsong ^a   Mao, Ying ^a   Li, Shiqi ^a   Zhao, Yao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Acromegaly; Pituitary macroadenomas; Presurgical long acting octreotide treatment

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ABSENCE OF SIDE EFFECTS; ACROMEGALY; ADULT; ARTICLE; CHINA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS MACROADENOMA; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OCTREOTIDE; PITUITARY NEOPLASMS; POSTOPERATIVE PERIOD; PREMEDICATION; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650576094     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-203     Document Type: Article

References (30)

1. Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355: 2558-2573.
2. Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 152: 379-387.
3. Shou XF, Li SQ, Wang YF, Zhao Y, Jia PF, Zhou LF (2005) Treatment of pituitary adenomas with a trans-sphenoidal approach. Neurosurgery 56: 249-256.
4. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoi-dal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58: 86-91.
5. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86: 4072-4077.
6. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G (2008) Growth hormone-secreting tumor shrinkage after 3 months of octreotide-LAR therapy predicts the response at 12 months. J Clin Endocrinol Metab 93:3436-3442.
7. Vallette S, Serri O (2008) Octreotide LAR for the treatment of acromegaly. Expert Opin Drug Metab Toxicol 4: 783-793.
8. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Benefcial effect of dose escalation of octreotide-LAR as frst-line therapy in patients with acromegaly. Eur J Endocrinol 157: 579-587.
9. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multi-centre study to investigate the effcacy, safety and tol-erability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66: 859-868.
10. Turner HE, Thornton-Jones VA, Wass JA (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol (Oxf) 61: 224-231.
11. Bolanowski M, Bar-Andziak E, Kos-Kudla B, Krzyzanowska-Swiniarska B, Lewinski A, Lomna-Bogdanov E, Milewicz A, Sowinski J, Zgliczynski W (2008) Consensus statement of the Polish Society for Endocrinology: presurgical somatostatin analogs therapy in acromegaly. Neuro Endocrinol Lett 29: 59-62.
12. Yin J, Su CB, Xu ZQ, Yang Y, Ma WB, Tao W, Yang Z, Xia XW (2005) Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. Chin Med Sci J 20: 23-26.
13. Plockinger U, Quabbe HJ (2005) Presurgical oct-reotide treatment in acromegaly: no improvement of fnal growth hormone (GH) concentration and pituitary function. A long-term case-control study. Acta Neurochir (Wien) 147: 485-493.
14. Sadoul JL (1999) Somatotrope pituitary adenomas. Contribution of presurgical treatment with soma-tostatin analogs. Ann Endocrinol (Paris) 60: 490-493.
15. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alferi A, Merola B, Cali A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308-3314.
16. Ayuk J, Stewart SE, Stewart PM, Sheppard MC (2004) Effcacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 60: 375-381.
17. Colao A, Pivonello R, Marzullo P, Auriemma RS, De Martino MC, Ferone D, Lombardi G (2005) Severe systemic complications of acromegaly. J Endocrinol Invest 28: 65-77.
18. Wilson CB (1984) A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg 61: 814-833.
19. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054-4058.
20. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. (2004) AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 10: 213-225.
21. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94: 1509-1517.
22. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, Barausse M, Albizzi M, Dallabonzana D, Pedroncelli AM (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098.
23. Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83: 2646-2652.
24. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, Cooper JG, Hald JK, Fougner SL, Bollerslev J (2008) Preoperative oct-reotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab 93: 2984-2990.
25. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J 53: 125-132.
26. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignano T, Giovanelli M (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104: 899-906.
27. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromeg-aly? A randomized study. Acta Neurochir (Wien) 141: 399-405.
28. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, Barcelo B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10-14.
29. Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafe A, Ducasse M, Harris AG, Bayard F (1989) Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 68: 917-924.
30. Schmitt H, Buchfelder M, Radespiel-Troger M, Fahlbusch R (2000) Diffcult intubation in acro-megalic patients: incidence and predictability. Anesthesiology 93: 110-114.